Perioperative immunotherapy for hepatocellular carcinoma: adjuvant, neoadjuvant, and biomarker-guided strategies
Hepatocellular carcinoma (HCC) remains difficult to cure after resection or ablation, with high recurrence rates. Perioperative immunotherapy has rapidly evolved, but recent late-phase readouts highlight that benefit is not universal. In IMbrave050, adjuvant atezolizumab plus bevacizumab initially i...
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Frontiers Media S.A.
2026-04-01
|
| Cyfres: | Frontiers in Medicine |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontiersin.org/articles/10.3389/fmed.2026.1811918/full |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|